Drug Profile
Research programme: malaria vaccines - Leidos Holdings/National Institute of Allergy and Infectious Diseases
Alternative Names: Circumsporozoite protein-based vaccine - Leidos/NIAID; CSP antigen - Leidos/NIAID; Plasmodium falciparum-based vaccines - Leidos/NIAID; Px 533; Reticulocyte-binding homologue 5-based vaccine - Leidos/NIAID; Rh5 antigen - Leidos/NIAIDLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Leidos Holdings
- Developer Leidos Holdings; National Institute of Allergy and Infectious Diseases
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA (Parenteral)